No sur­prise: Ab­b­Vie turns cold shoul­der to a messy rheuma­toid arthri­tis part­ner­ship with Abl­ynx

Ab­b­Vie is punt­ing yet an­oth­er high-pro­file rheuma­toid arthri­tis de­vel­op­ment part­ner­ship. The phar­ma out­fit is tak­ing a pass on Abl­ynx’s Phase III-ready drug vo­bar­il­izum­ab and shrug­ging …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.